Meningococcal group Y polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup Y. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and... It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.
- First approval
- Canada, 2000 · United States, 1981 · European Union, 2020
- Also known as
- Meningococcal polysaccharide antigen group Y · Neisseria meningitidis group Y capsular polysaccharide antigen · Neisseria meningitidis group Y polysaccharide antigen, A
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Meningococcal polysaccharide vaccine group Y, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account